Targeting Msx2 as a brake in the fusion fate of osteoclasts and an anabolic therapy in pre-clinical models of osteoporosis.
以 Msx2 为靶点，抑制破骨细胞的融合命运，并在骨质疏松症的临床前模型中发挥合成代谢治疗作用
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-61938-0
Ma Qingliang, Wang Shiyu, Xue Hong, Ni Linhui, Yuan Putao, Shen Yang, Zheng Bingjie, Wang Qingqing, Zhang Jiateng, Wang Haoming, Xie Hongwei, Jiang Chao, Qin An, Fan Shunwu, Xie Ziang, Jie Zhiwei
